Dossier assessment
Deucravacitinib (plaque psoriasis) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Deucravacitinib (plaque psoriasis) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Deucravacitinib (plaque psoriasis) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Indication:
Adult patients with moderate to severe plaque psoriasis
Result of dossier assessment:
- Patients who are not candidates for conventional treatment in the context of initial systemic therapy: added benefit not proven
- Patients who have responded inadequately or who have been intolerant to systemic therapy: added benefit not proven
Project details
- Project no.
- A23-34
- Commission
- Commission awarded on 17.04.2023 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Skin and hair
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Dossier assessment
Deucravacitinib (psoriatic arthritis) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed